{"schema_version":"secwatch.filing_event.v1","accession":"0001615219-26-000013","form_type":"8-K","ticker":"DCOY","cik":"0001615219","company_name":"Decoy Therapeutics Inc.","filed_at":"2026-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.647538+00:00","generated_at":"2026-05-16T11:12:49.384943+00:00","sec_items":["5.03","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"confidence":"high","headline":"Salarius Pharmaceuticals renames to Decoy Therapeutics; ticker changes to DCOY effective Jan 8, 2026","bullets":["Name change to Decoy Therapeutics Inc. and ticker symbol change from SLRX to DCOY effective January 8, 2026.","No change to shares outstanding, shareholder rights, CUSIP number, or transfer agent.","Focus on AI-enabled peptide-conjugate platform; lead antiviral program attracts BARDA interest.","2026 priorities: advance lead into clinic, expand pipeline, pursue partnerships, and strengthen capital structure.","Company to launch new website decoytx.com for investor relations."],"urls":{"canonical":"https://secwatch.observer/filing/0001615219-26-000013","json":"https://secwatch.observer/filing/0001615219-26-000013.json","markdown":"https://secwatch.observer/filing/0001615219-26-000013.md","text":"https://secwatch.observer/filing/0001615219-26-000013.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1615219/000161521926000013/0001615219-26-000013-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1615219/000161521926000013/flks-20260108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:12:49.384943+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}